JP Morgan lowers price targets on Cytokinetics and Enanta, keeps Overweight ratings
JP Morgan kept Overweight ratings on two biotech stocks while cutting targets: Cytokinetics to $100 and Enanta Pharmaceuticals to $17.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
JP Morgan kept its Overweight rating on Cytokinetics and cut its price target to $100 from $103, a 2.9% reduction. According to TradingView, citing Benzinga data, the target was set against the November 19 close of $51.46.
The bank also kept an Overweight rating on Enanta Pharmaceuticals and lowered its target to $17 from $19, a 10.5% cut. The stock closed at $7.98 on November 19.
why it matters
Updates like these reflect a single analyst's revised valuation of individual companies, so their effect on the broader market is usually small. For biotech investors, clinical trial progress and company earnings typically matter more than one adjustment to a price target.
tags
instruments
sources
- JP Morgan maintains Cytokinetics at Overweight, lowers price target to $100 from $103 — TradingView, 20 November 2026 at 17:51 UTC
- JP Morgan maintains Enanta Pharmaceuticals at Overweight, lowers price target to $17 from $19 — TradingView, 20 November 2026 at 17:54 UTC
- JP Morgan maintains IDEAYA Biosciences at Overweight, lowers price target to $55 from $62 — TradingView, 20 November 2026 at 18:00 UTC
- JP Morgan maintains Firefly Aerospace at Overweight, lowers price target to $32 from $40 — TradingView, 20 November 2026 at 17:55 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗